Acorda Therapeutics, Inc. (CDG.F)

8,42 0,00 (0,00%) Börsenschluss: 03:32PM CEST

Acorda Therapeutics, Inc.

2 Blue Hill Plaza
3rd Floor
Pearl River, NY 10965
United States
914 347 4300
https://www.acorda.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 102

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Ron Cohen M.D.	Founder, CEO, President & Director	833,47k	N/A	1956
Mr. Michael A. Gesser M.B.A.	CFO & Treasurer	567,99k	N/A	1963
Mr. Neil S. Belloff Esq.	General Counsel & Corporate Secretary	572,37k	N/A	1960
Ms. Denise J. Duca	Executive Vice President of Human Resources	N/A	N/A	N/A
Mr. Kerry M. Clem	Chief Commercial Officer	550,04k	N/A	1970
Sofia Ali	Senior VP of Operations & Strategic Planning	N/A	N/A	N/A
Susan Way	Senior VP of Drug Development & Regulatory Affairs	N/A	N/A	N/A
Dr. Wise Young M.D., Ph.D.	Special Scientific Advisor	9,29k	N/A	1950

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Corporate Governance

Acorda Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 9, Vorstand: 5, Shareholderrechte: 7, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.